Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONSUL: celecoxib added to golimumab versus golimumab alone in ankylosing spondylitis
2016-000615-33Phase 4Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in ankylosing spondylitis (AS) comparing Celecoxib + golimumab with Golimumab alone (2 arms). Primary endpoint: Absolute progression of syndesmophytes by mSASSS. Started Jul 2016; status: completed.
02
Drugs
celecoxibgolimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2016-000615-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000615-33.